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Vitamin D May Enhance ALA Photodynamic Therapy
Photodynamic therapy 
(PDT) with 5-aminolevu-
linic acid (ALA) is based 
on the synthesis of proto-
porphyrin IX (PpIX), which 
absorbs light and targets 
metabolically active cells. 
Sato and coworkers tested 
whether levels of PpIX within keratinocytes might be increased by vitamin D. Four 
hours after addition of ALA, PpIX levels were increased in the vitamin D–precondi-
tioned cultures of rat epidermal keratinocytes; likewise, phototoxic cell killing after 
light exposure was higher in these cultures. Vitamin D may be useful as a biological 
enhancer of ALA-based photodynamic therapy, and this could have clinical impli-
cations. See page 925 
Viral or Drug? sFASL Can Help
Stur and co-workers looked for the presence of Fas 
ligand in sera and skin sections from 42 patients with 
maculopapular rashes (MPRs) and compared their 
result to specimens from four patients with toxic 
epidermal necrolysis (TEN) and two with Stevens–
Johnson syndrome. Specimens from 26 patients with 
viral exanthemas and 134 patients with inflammato-
ry skin diseases served as controls. Elevated levels of 
soluble Fas ligand (sFASL) were detected in sera from 
patients with TEN and MPR, but sFASL was repeat-
edly negative in all viral exanthemas and healthy 
controls. sFASL serum concentrations may represent 
a tool to discriminate between drug and viral rashes. 
See page 802
Oral Chymase Inhibitor Improves Dermatitis
A chymase inhibitor has been shown to 
improve atopic dermatitis (AD) in animal 
models, but only when given intraperito-
neally or in drinking water. Watanabe and 
colleagues synthesized a chymase inhibitor 
with an improved profile, SUN13350, and 
studied the effects of once-daily oral admin-
istration, at 30 mg/kg, to NC/Nga mice 
for 3 weeks beginning at 8 weeks old. The 
improved AD in SUN13350-treated NC/
Nga mice, they theorize, might be the effect 
of inhibition of SCF processing and eosinophil infiltration. Because SUN13350 has 
been shown to have these same effects in humans, this may be a promising oral 
agent for AD. See page 971
S100A7 in Wound 
Healing
S100A7, also called psoriasin, 
is a protein that is highly 
expressed in epidermal 
hyperproliferative diseases. 
Studies using recombinant 
S100A7 indicate that it adheres 
to and reduces Escherichia 
coli survival. Lee and Eckert 
have demonstrated that the 
central region of S100A7, 
including only amino acids 
35–80, is sufficient for full 
antibacterial activity, and that 
reduced S100A7 interaction 
with bacteria is associated with 
reduced antibacterial activity. 
Smaller peptides may be more 
attractive for clinical use. See 
page 945
DMF: A Potent 
Immunosuppressor
When Lehmann and 
colleagues analyzed the 
effect of fumaric acid esters 
(FAEs) on in vitro immune 
function, they found that 
dimethylfumarate (DMF) 
and diethylfumarate 
(DEF) strongly depressed 
inflammatory cytokine 
secretion in activated 
human peripheral blood 
mononuclear cells. This and 
other immunosuppressive 
effects were accompanied 
by the strong induction of 
the anti-inflammatory stress 
protein heme oxygenase 
1 (HO-1). These findings 
suggest that DMF acts as an 
active compound within the 
FAE mixture and that the 
induction of HO-1 expression 
is a central anti-inflammatory 
mechanism that may play a 
major role in immune therapy 
with FAEs. See page 835 
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